Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Комбинированный препарат растительного происхождения в терапии пациентов с функциональными расстройствами пищеварительной системы
Комбинированный препарат растительного происхождения в терапии пациентов с функциональными расстройствами пищеварительной системы
Бакулин И.Г., Сказываева Е.В., Авалуева Е.Б. и др. Комбинированный препарат растительного происхождения в терапии пациентов с функциональными расстройствами пищеварительной системы. Consilium Medicum. 2017; 19 (8): 54–61. DOI: 10.26442/2075-1753_19.8.54-61
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В последние годы отмечается увеличение числа пациентов с функциональными заболеваниями желудочно-кишечного тракта, причем нередко имеют место сочетание разных вариантов функциональных расстройств, а также их комбинация с другими заболеваниями желудочно-кишечного тракта. В связи с этим возникает необходимость поиска новых эффективных подходов в лечении данной группы пациентов, которые помогут избежать одновременного назначения нескольких лекарственных средств. Одним из таких терапевтических подходов является назначение комбинированного препарата растительного происхождения STW 5 (Иберогаст®), воздействующего на разные патогенетические механизмы функциональных расстройств. Входящие в состав препарата компоненты обладают синергическим эффектом, потенцируя действия друг друга. У пациентов с функциональными расстройствами препарат может использоваться как в виде монотерапии, так и в составе комплексного лечения. Эффективность и безопасность STW 5 в лечении функциональных заболеваний пищеварительного тракта были показаны в большом количестве клинических исследований и соответствуют уровню доказательности IА.
Ключевые слова: функциональные расстройства желудочно-кишечного тракта, функциональная диспепсия, синдром раздраженного кишечника, Римские критерии IV, Иберогаст.
Key words: functional disorders of the gastrointestinal tract, functional dyspepsia, irritable bowel syndrome, Rome IV criteria, Iberogast.
Ключевые слова: функциональные расстройства желудочно-кишечного тракта, функциональная диспепсия, синдром раздраженного кишечника, Римские критерии IV, Иберогаст.
________________________________________________
Key words: functional disorders of the gastrointestinal tract, functional dyspepsia, irritable bowel syndrome, Rome IV criteria, Iberogast.
Полный текст
Список литературы
1. Drossman DA, Hasler WL. Rome IV – Functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016; 150 (6): 1257–61.
2. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Синдром раздраженного кишечника. Римские критерии IV. Consilium Medicum. 2016; 18 (8): 79–85. / Maev I.V., Cheremushkin S.V., Kucheriavyi Iu.A., Cheremushkina N.V. Irritable bowel syndrome. Rome criteria IV. Consilium Medicum. 2016; 18 (8): 79–85. [in Russian]
3. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 150: 1262–79.
4. Jones MP, Dilley JB, Drossman D et al. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91–103.
5. Шептулин А.А., Курбатова А.А. Новые Римские критерии функциональной диспепсии IV пересмотра. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 124–8. / Sheptulin A.A., Kurbatova A.A. Novye Rimskie kriterii funktsionalnoi dispepsii IV peresmotra. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 124–8. [in Russian]
6. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282–4.
7. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
8. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671–80.
9. Keohane J. Functional Dyspepsia and Nonerosive Reflux Disease: Clinical Interactions and Their Implications. Med Gen Med 2007; 9 (3): 31.
10. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46 (3): 175–90.
11. Young Wook Noh MD, Hye-Kyung Jung MD, Seong-Eun Kim MD, Sung-Ae Jung MD. Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil 2010; 16 (2). DOI: 10.5056/jnm.2010.16.2.148
12. Калинин А.В., Логинов А.В., Хазанов А.И. Гастроэнтерология и гепатология: диагностика и лечение. Руководство для врачей. М.: МЕДпресс-информ, 2013 г. / Kalinin A.V., Loginov A.V., Khazanov A.I. Gastroenterologia I gepatologia: diagnostika I lechenie. Rukovodstvo dlia vrachei. M.: MEDpress-inform, 2013. [in Russian]
13. Авалуева Е.Б., Ткаченко Е.И., Сказываева Е.В. и др. Использование препаратов висмута в лечении синдрома раздраженного кишечника. Гастроэнтерология Санкт-Петербурга. 2013; 3–4: 11–4. / Avalueva E.B., Tkachenko E.I., Skazyvaeva E.V. i dr. Ispolzovanie preparatov vismuta v lechenii sindroma razdrazhennogo kishechnika. Gastroenterologiia Sankt-Peterburga. 2013; 3–4: 11–4. [in Russian]
14. Белоусова Л.Н., Пахомова И.Г. Синдром раздраженного кишечника. Новые возможности фармакопротекции РМЖ. Мед. обозрение. Клинические рекомендации и алгоритмы для практикующих врачей. Гастроэнтерология. 2014; 31: 2222–6. / Belousova L.N., Pakhomova I.G. Sindrom razdrazhennogo kishechnika. Novye vozmozhnosti farmakoprotektsii RMZh. Med. obozrenie. Klinicheskie rekomendatsii i algoritmy dlia praktikuiushchikh vrachei. Gastroenterologiia. 2014; 31: 2222–6. [in Russian]
15. Itokawa H, Morris-Natschke SL, Akiyama T, Lee KH. Plant-derived natural product research aimed at new drug discovery. Nat Med 2008; 62: 263–80.
16. Njuguna NM, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products-driven drug discovery. Nat Prod 2012; 75: 507–13.
17. Vinson B. Development of Iberogast®: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167–89.
18. Мазнев Н.И. Энциклопедия лекарственных средств. 3-е изд., испр. и доп. М., 2004. / Maznev N.I. Entsiklopediia lekarstvennykh sredstv. 3-e izd., ispr. i dop. M., 2004. [in Russian]
19. Heinle H, Hagelauer D, Pascht U et al. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75–9.
20. Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of STW 5 (Iberogast) in intestinal smooth muscle. Phytomedicine 2006; 13: SV 67–74.
21. Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759–64.
22. Simmen U, Kelber O, Okpanyi SN et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13: 51–5.
23. Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA et al. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound activity. Phytomedicine 2006; 13: SV 56–66.
24. Khayyal MT, El-Ghazaly MA, Kenawy SА et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittel Forsch/Drug Res 2001; 51: 545–53.
25. Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim-Forsch/Drug Res 2003; 53 (8): 568–77.
26. Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: 143–9.
27. Michael S, Kelber O, Vinson B, Nieber K. Herbal preparations STW 5 and STW 6 inhibit inflammation- mediated motility disorders in the ileum. Gut 2006; 55: SV A206.
28. Abdel-Aziz H, Wadie W, Kelber O et al. Anti inflammatory effect of STW5 in colonic inflammation in vivo. Gut 2007; 56: A154.
29. Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti infl ammatory properties of STW 5 and its components. Phytomedicine 2006; 13: SV 36–44.
30. Kruger D, Zeller F, Kellber O et al. The phytopharmacon STW 5 (Iberogast) has pro-secretory effects of the human small and large intestine. Gut 2007; 55 (Suppl. V): A94.
31. Ritter R et al. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo-controlled double-blind trial. Complement Ther Med 1993; 1: 189–93.
32. Harries N et al. Antifoaming and carminativeaction of volatile oils. J Clin Pharmacy 1978; 2: 171–7.
33. Krüger D, Gruber L, Angay O et al. Efficacy profile of STW 5 (Iberogast) offers new options for treatment of gastrointestinal diseases. Z Phytother 2008; 29: S29.
34. Schemann M, Michel K, Hohenester B, Rühl A. Region specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90–9.
35. Pilichiewicz AN, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1–8.
36. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with functional dyspepsia and irritable bowel syndrome. Gastroenterology 2013; 144 (5, Supp. 1): 682 (Mo1881).
37. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
2. Maev I.V., Cheremushkin S.V., Kucheriavyi Iu.A., Cheremushkina N.V. Irritable bowel syndrome. Rome criteria IV. Consilium Medicum. 2016; 18 (8): 79–85. [in Russian]
3. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 150: 1262–79.
4. Jones MP, Dilley JB, Drossman D et al. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91–103.
5. Sheptulin A.A., Kurbatova A.A. Novye Rimskie kriterii funktsionalnoi dispepsii IV peresmotra. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 124–8. [in Russian]
6. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282–4.
7. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
8. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671–80.
9. Keohane J. Functional Dyspepsia and Nonerosive Reflux Disease: Clinical Interactions and Their Implications. Med Gen Med 2007; 9 (3): 31.
10. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46 (3): 175–90.
11. Young Wook Noh MD, Hye-Kyung Jung MD, Seong-Eun Kim MD, Sung-Ae Jung MD. Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil 2010; 16 (2). DOI: 10.5056/jnm.2010.16.2.148
12. Kalinin A.V., Loginov A.V., Khazanov A.I. Gastroenterologia I gepatologia: diagnostika I lechenie. Rukovodstvo dlia vrachei. M.: MEDpress-inform, 2013. [in Russian]
13. Avalueva E.B., Tkachenko E.I., Skazyvaeva E.V. i dr. Ispolzovanie preparatov vismuta v lechenii sindroma razdrazhennogo kishechnika. Gastroenterologiia Sankt-Peterburga. 2013; 3–4: 11–4. [in Russian]
14. Belousova L.N., Pakhomova I.G. Sindrom razdrazhennogo kishechnika. Novye vozmozhnosti farmakoprotektsii RMZh. Med. obozrenie. Klinicheskie rekomendatsii i algoritmy dlia praktikuiushchikh vrachei. Gastroenterologiia. 2014; 31: 2222–6. [in Russian]
15. Itokawa H, Morris-Natschke SL, Akiyama T, Lee KH. Plant-derived natural product research aimed at new drug discovery. Nat Med 2008; 62: 263–80.
16. Njuguna NM, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products-driven drug discovery. Nat Prod 2012; 75: 507–13.
17. Vinson B. Development of Iberogast®: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167–89.
18. Maznev N.I. Entsiklopediia lekarstvennykh sredstv. 3-e izd., ispr. i dop. M., 2004. [in Russian]
19. Heinle H, Hagelauer D, Pascht U et al. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75–9.
20. Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of STW 5 (Iberogast) in intestinal smooth muscle. Phytomedicine 2006; 13: SV 67–74.
21. Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759–64.
22. Simmen U, Kelber O, Okpanyi SN et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13: 51–5.
23. Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA et al. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound activity. Phytomedicine 2006; 13: SV 56–66.
24. Khayyal MT, El-Ghazaly MA, Kenawy SА et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittel Forsch/Drug Res 2001; 51: 545–53.
25. Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim-Forsch/Drug Res 2003; 53 (8): 568–77.
26. Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: 143–9.
27. Michael S, Kelber O, Vinson B, Nieber K. Herbal preparations STW 5 and STW 6 inhibit inflammation- mediated motility disorders in the ileum. Gut 2006; 55: SV A206.
28. Abdel-Aziz H, Wadie W, Kelber O et al. Anti inflammatory effect of STW5 in colonic inflammation in vivo. Gut 2007; 56: A154.
29. Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti infl ammatory properties of STW 5 and its components. Phytomedicine 2006; 13: SV 36–44.
30. Kruger D, Zeller F, Kellber O et al. The phytopharmacon STW 5 (Iberogast) has pro-secretory effects of the human small and large intestine. Gut 2007; 55 (Suppl. V): A94.
31. Ritter R et al. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo-controlled double-blind trial. Complement Ther Med 1993; 1: 189–93.
32. Harries N et al. Antifoaming and carminativeaction of volatile oils. J Clin Pharmacy 1978; 2: 171–7.
33. Krüger D, Gruber L, Angay O et al. Efficacy profile of STW 5 (Iberogast) offers new options for treatment of gastrointestinal diseases. Z Phytother 2008; 29: S29.
34. Schemann M, Michel K, Hohenester B, Rühl A. Region specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90–9.
35. Pilichiewicz AN, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1–8.
36. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with functional dyspepsia and irritable bowel syndrome. Gastroenterology 2013; 144 (5, Supp. 1): 682 (Mo1881).
37. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
2. Маев И.В., Черемушкин С.В., Кучерявый Ю.А., Черемушкина Н.В. Синдром раздраженного кишечника. Римские критерии IV. Consilium Medicum. 2016; 18 (8): 79–85. / Maev I.V., Cheremushkin S.V., Kucheriavyi Iu.A., Cheremushkina N.V. Irritable bowel syndrome. Rome criteria IV. Consilium Medicum. 2016; 18 (8): 79–85. [in Russian]
3. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 150: 1262–79.
4. Jones MP, Dilley JB, Drossman D et al. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91–103.
5. Шептулин А.А., Курбатова А.А. Новые Римские критерии функциональной диспепсии IV пересмотра. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 124–8. / Sheptulin A.A., Kurbatova A.A. Novye Rimskie kriterii funktsionalnoi dispepsii IV peresmotra. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 124–8. [in Russian]
6. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282–4.
7. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
8. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671–80.
9. Keohane J. Functional Dyspepsia and Nonerosive Reflux Disease: Clinical Interactions and Their Implications. Med Gen Med 2007; 9 (3): 31.
10. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46 (3): 175–90.
11. Young Wook Noh MD, Hye-Kyung Jung MD, Seong-Eun Kim MD, Sung-Ae Jung MD. Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil 2010; 16 (2). DOI: 10.5056/jnm.2010.16.2.148
12. Калинин А.В., Логинов А.В., Хазанов А.И. Гастроэнтерология и гепатология: диагностика и лечение. Руководство для врачей. М.: МЕДпресс-информ, 2013 г. / Kalinin A.V., Loginov A.V., Khazanov A.I. Gastroenterologia I gepatologia: diagnostika I lechenie. Rukovodstvo dlia vrachei. M.: MEDpress-inform, 2013. [in Russian]
13. Авалуева Е.Б., Ткаченко Е.И., Сказываева Е.В. и др. Использование препаратов висмута в лечении синдрома раздраженного кишечника. Гастроэнтерология Санкт-Петербурга. 2013; 3–4: 11–4. / Avalueva E.B., Tkachenko E.I., Skazyvaeva E.V. i dr. Ispolzovanie preparatov vismuta v lechenii sindroma razdrazhennogo kishechnika. Gastroenterologiia Sankt-Peterburga. 2013; 3–4: 11–4. [in Russian]
14. Белоусова Л.Н., Пахомова И.Г. Синдром раздраженного кишечника. Новые возможности фармакопротекции РМЖ. Мед. обозрение. Клинические рекомендации и алгоритмы для практикующих врачей. Гастроэнтерология. 2014; 31: 2222–6. / Belousova L.N., Pakhomova I.G. Sindrom razdrazhennogo kishechnika. Novye vozmozhnosti farmakoprotektsii RMZh. Med. obozrenie. Klinicheskie rekomendatsii i algoritmy dlia praktikuiushchikh vrachei. Gastroenterologiia. 2014; 31: 2222–6. [in Russian]
15. Itokawa H, Morris-Natschke SL, Akiyama T, Lee KH. Plant-derived natural product research aimed at new drug discovery. Nat Med 2008; 62: 263–80.
16. Njuguna NM, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products-driven drug discovery. Nat Prod 2012; 75: 507–13.
17. Vinson B. Development of Iberogast®: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167–89.
18. Мазнев Н.И. Энциклопедия лекарственных средств. 3-е изд., испр. и доп. М., 2004. / Maznev N.I. Entsiklopediia lekarstvennykh sredstv. 3-e izd., ispr. i dop. M., 2004. [in Russian]
19. Heinle H, Hagelauer D, Pascht U et al. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75–9.
20. Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of STW 5 (Iberogast) in intestinal smooth muscle. Phytomedicine 2006; 13: SV 67–74.
21. Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759–64.
22. Simmen U, Kelber O, Okpanyi SN et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13: 51–5.
23. Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA et al. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound activity. Phytomedicine 2006; 13: SV 56–66.
24. Khayyal MT, El-Ghazaly MA, Kenawy SА et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittel Forsch/Drug Res 2001; 51: 545–53.
25. Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim-Forsch/Drug Res 2003; 53 (8): 568–77.
26. Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: 143–9.
27. Michael S, Kelber O, Vinson B, Nieber K. Herbal preparations STW 5 and STW 6 inhibit inflammation- mediated motility disorders in the ileum. Gut 2006; 55: SV A206.
28. Abdel-Aziz H, Wadie W, Kelber O et al. Anti inflammatory effect of STW5 in colonic inflammation in vivo. Gut 2007; 56: A154.
29. Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti infl ammatory properties of STW 5 and its components. Phytomedicine 2006; 13: SV 36–44.
30. Kruger D, Zeller F, Kellber O et al. The phytopharmacon STW 5 (Iberogast) has pro-secretory effects of the human small and large intestine. Gut 2007; 55 (Suppl. V): A94.
31. Ritter R et al. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo-controlled double-blind trial. Complement Ther Med 1993; 1: 189–93.
32. Harries N et al. Antifoaming and carminativeaction of volatile oils. J Clin Pharmacy 1978; 2: 171–7.
33. Krüger D, Gruber L, Angay O et al. Efficacy profile of STW 5 (Iberogast) offers new options for treatment of gastrointestinal diseases. Z Phytother 2008; 29: S29.
34. Schemann M, Michel K, Hohenester B, Rühl A. Region specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90–9.
35. Pilichiewicz AN, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1–8.
36. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with functional dyspepsia and irritable bowel syndrome. Gastroenterology 2013; 144 (5, Supp. 1): 682 (Mo1881).
37. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
________________________________________________
2. Maev I.V., Cheremushkin S.V., Kucheriavyi Iu.A., Cheremushkina N.V. Irritable bowel syndrome. Rome criteria IV. Consilium Medicum. 2016; 18 (8): 79–85. [in Russian]
3. Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology 2016; 150: 1262–79.
4. Jones MP, Dilley JB, Drossman D et al. Brain-gut connections in functional GI disorders: anatomic and physiologic relationships. Neurogastroenterol Motil 2006; 18: 91–103.
5. Sheptulin A.A., Kurbatova A.A. Novye Rimskie kriterii funktsionalnoi dispepsii IV peresmotra. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 124–8. [in Russian]
6. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282–4.
7. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
8. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: Overlap and lack of stability over time. Gastroenterology 1995; 109: 671–80.
9. Keohane J. Functional Dyspepsia and Nonerosive Reflux Disease: Clinical Interactions and Their Implications. Med Gen Med 2007; 9 (3): 31.
10. Oustamanolakis P, Tack J. Dyspepsia: organic versus functional. J Clin Gastroenterol 2012; 46 (3): 175–90.
11. Young Wook Noh MD, Hye-Kyung Jung MD, Seong-Eun Kim MD, Sung-Ae Jung MD. Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil 2010; 16 (2). DOI: 10.5056/jnm.2010.16.2.148
12. Kalinin A.V., Loginov A.V., Khazanov A.I. Gastroenterologia I gepatologia: diagnostika I lechenie. Rukovodstvo dlia vrachei. M.: MEDpress-inform, 2013. [in Russian]
13. Avalueva E.B., Tkachenko E.I., Skazyvaeva E.V. i dr. Ispolzovanie preparatov vismuta v lechenii sindroma razdrazhennogo kishechnika. Gastroenterologiia Sankt-Peterburga. 2013; 3–4: 11–4. [in Russian]
14. Belousova L.N., Pakhomova I.G. Sindrom razdrazhennogo kishechnika. Novye vozmozhnosti farmakoprotektsii RMZh. Med. obozrenie. Klinicheskie rekomendatsii i algoritmy dlia praktikuiushchikh vrachei. Gastroenterologiia. 2014; 31: 2222–6. [in Russian]
15. Itokawa H, Morris-Natschke SL, Akiyama T, Lee KH. Plant-derived natural product research aimed at new drug discovery. Nat Med 2008; 62: 263–80.
16. Njuguna NM, Masimirembwa C, Chibale K. Identification and characterization of reactive metabolites in natural products-driven drug discovery. Nat Prod 2012; 75: 507–13.
17. Vinson B. Development of Iberogast®: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert, 2009; p. 167–89.
18. Maznev N.I. Entsiklopediia lekarstvennykh sredstv. 3-e izd., ispr. i dop. M., 2004. [in Russian]
19. Heinle H, Hagelauer D, Pascht U et al. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75–9.
20. Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of STW 5 (Iberogast) in intestinal smooth muscle. Phytomedicine 2006; 13: SV 67–74.
21. Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast®) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759–64.
22. Simmen U, Kelber O, Okpanyi SN et al. Bimding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors. Phytomedicine 2006; 13: 51–5.
23. Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA et al. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound activity. Phytomedicine 2006; 13: SV 56–66.
24. Khayyal MT, El-Ghazaly MA, Kenawy SА et al. Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittel Forsch/Drug Res 2001; 51: 545–53.
25. Schempp H, Totha A, Weiser D, Elstnera E. Antioxidative Properties of Iberis amara Extracts in Biochemical Model Reactions. Arzneim-Forsch/Drug Res 2003; 53 (8): 568–77.
26. Germann I et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast®). Phytomedicine 2006; 13: 143–9.
27. Michael S, Kelber O, Vinson B, Nieber K. Herbal preparations STW 5 and STW 6 inhibit inflammation- mediated motility disorders in the ileum. Gut 2006; 55: SV A206.
28. Abdel-Aziz H, Wadie W, Kelber O et al. Anti inflammatory effect of STW5 in colonic inflammation in vivo. Gut 2007; 56: A154.
29. Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti infl ammatory properties of STW 5 and its components. Phytomedicine 2006; 13: SV 36–44.
30. Kruger D, Zeller F, Kellber O et al. The phytopharmacon STW 5 (Iberogast) has pro-secretory effects of the human small and large intestine. Gut 2007; 55 (Suppl. V): A94.
31. Ritter R et al. Clinical trial on standardised celandine extract in patients with functional epigastric complaints: results of a placebo-controlled double-blind trial. Complement Ther Med 1993; 1: 189–93.
32. Harries N et al. Antifoaming and carminativeaction of volatile oils. J Clin Pharmacy 1978; 2: 171–7.
33. Krüger D, Gruber L, Angay O et al. Efficacy profile of STW 5 (Iberogast) offers new options for treatment of gastrointestinal diseases. Z Phytother 2008; 29: S29.
34. Schemann M, Michel K, Hohenester B, Rühl A. Region specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90–9.
35. Pilichiewicz AN, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal (APD) motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102: 1–8.
36. Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with functional dyspepsia and irritable bowel syndrome. Gastroenterology 2013; 144 (5, Supp. 1): 682 (Mo1881).
37. Ottillinger B et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65–72.
Авторы
И.Г.Бакулин*, Е.В.Сказываева, Е.Б.Авалуева, М.И.Скалинская, И.А.Оганезова
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41
*igbakulin@yandex.ru
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
*igbakulin@yandex.ru
ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И.Мечникова» Минздрава России. 191015, Россия, Санкт-Петербург, ул. Кирочная, д. 41
*igbakulin@yandex.ru
________________________________________________
I.I.Mechnikov North-West State Medical University of the Ministry of Health of the Russian Federation. 191015, Russian Federation, Saint Petersburg, ul. Kirochnaia, d. 41
*igbakulin@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.